3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Colorectal Neoplasms
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Gallbladder Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
36
Magnetic Resonance Spectroscopy
23
Gemcitabine
19
Specimen Handling
15
Nivolumab
12
Carboplatin
12
Surveys and Questionnaires
11
Paclitaxel
11
Cetuximab
11
Early Intervention, Educational
10
Bevacizumab
10
Standard of Care
9
Cyclophosphamide
9
Cisplatin
9
Radiosurgery
8
Methods
8
Fluorouracil
8
Docetaxel
8
Blood Specimen Collection
8
Psychiatric Rehabilitation
7
Pemetrexed
7
sargramostim
6
aldesleukin
6
Taxes
6
Injections
6
Fluorodeoxyglucose F18
6
Educational Status
6
Drug Therapy
6
Biopsy
6
Albumin-Bound Paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Desflurane
×
Gastrointestinal
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled